The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
News|Articles|August 20, 2007
Weight loss: The pendulum swings again
Organized by HBC category, the never-out list is Hamacher Resource Group's proprietary list of products that pharmacy shelves should never be without. The following is a partial list of never-outs from the weight-control category.
Advertisement
This article is contributed by Hamacher Resource Group (
Advertisement
Related to this article
The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.
A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
A guide built from conversations with pharmacists on social media and independent pharmacy owners.
Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.
Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
2
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
3
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5